Ocuphire Pharma enrolls first patient in VEGA-2 Phase 3 trial of Nyxol

Ocuphire Pharma announced the initiation of the VEGA-2 Phase 3 pivotal trial with the first patient enrolled in late December. VEGA-2 is evaluating the efficacy and safety for two labels: Nyxol alone and Nyxol with adjunctive low-dose pilocarpine therapy for presbyopia.